The Concurrent Therapeutic Potential of Adipose-derived Mesenchymal Stem Cells on Gentamycin-induced Hepatorenal Toxicity in Rats
Date
2022-11
Journal Title
Journal ISSN
Volume Title
Type
Book
Publisher
Bentham Science Publishers
Series Info
Current Stem Cell Research and Therapy;Volume 17, Issue 8, Pages 808 - 814November 2022
Scientific Journal Rankings
Abstract
Background: Adipose mesenchymal stem cells (AMSCs) are a type of stem cell employed to repair damaged organs. This study aimed to see how effective AMSCs are at treating gentamycin- induced hepatorenal damage in rats.
Methods: 18 male Wister rats were assigned into three groups; control, Gentamycin (GM), and GM+AMSCs. GM induced hepatorenal toxicity through daily injection (100 mg/kg, i.p.) for eight days. On day 9, AMSC (106 cells/ml/rat) was injected intravenously.
Results: Creatinine, urea, uric acid, AST, ALP, ALT, TNF-, and MDA levels decreased, whereas IL-10, GSH, and CAT levels increased, indicating the therapeutic potency of intravenous injection AMSCs.
Conclusion: The current study demonstrated the simultaneous therapeutic efficacy of adipose mesenchymal stem cells on the liver and kidney in the treatment of Gentamycin-induced hepatotoxicity. These data show that AMSCs could be a feasible therapy option for liver and kidney disease.
Description
Scopus
Keywords
Adipose-derived mesenchymal stem cells, gentamycin, aminoglycosides., hepatorenal toxicity, oxidative stress, histology, inflammation